Skip to main content
Transcenta Holding Limited logo

Transcenta Holding Limited — Investor Relations & Filings

Ticker · 6628 ISIN · KYG9005B1041 HKEX Manufacturing
Open in API
Filings indexed 482 across all filing types
Latest filing 2023-08-10 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6628

About Transcenta Holding Limited

http://www.transcenta.com

Transcenta Holding Limited is a clinical-stage global biotherapeutics company specializing in the discovery, research, development, and manufacturing of differentiated antibody-based therapeutics. The company operates a fully integrated platform, utilizing a unique antibody generation platform based on Immune Tolerance Breaking Technology to generate candidate leads. Its robust pipeline includes therapeutic antibody molecules targeting oncology and selected non-oncology indications, such as bone and kidney disorders. The company employs advanced bioprocessing technologies, including perfusion-based continuous bioprocessing, to accelerate process development and reduce manufacturing costs.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of Transcenta Holding Limited about the date of a board meeting to consider and approve the interim results for the six months ended June 30, 2023, and the recommendation of an interim dividend. The document does not contain the actual interim financial results or substantive financial data but merely announces the upcoming board meeting where these results will be considered. The document length is short (1565 characters) and serves as a notice rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement rather than an Interim Report (IR) or Earnings Release (ER).
2023-08-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Transcenta Holding Limited, including authorized share capital, issued shares, share options, and confirmations related to share issuance. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content focuses on share capital changes, share options, and confirmations of compliance with listing requirements. It does not contain financial statements, earnings data, or management discussion. It is a regulatory compliance filing related to share capital movements rather than a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2023-08-04 English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON THE RECEIVAL OF APPROVAL FROM CHINA CDE FOR THE COMPANY'S ANTI-SCLEROSTIN MONOCLONAL ANTIBODY TST002 (BLOSOZUMAB) TO INITIATE PHASE II CLINICAL TRIAL IN
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Transcenta Holding Limited regarding a business update about receiving approval from the China Center for Drug Evaluation (CDE) to initiate a Phase II clinical trial for their drug candidate TST002 (Blosozumab). It provides detailed information about the drug, clinical trial phases, and related scientific data. The document is not a full financial report, audit, or earnings release. It is not a regulatory filing or a report publication announcement since it contains substantive business update content rather than just a notice or link to a report. It is also not related to board changes, voting results, or capital changes. The content fits best under a voluntary business update announcement category, which aligns with Regulatory Filings (RNS) as a fallback for miscellaneous announcements that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-07-31 English
GRANT OF AWARD SHARES PURSUANT TO THE SHARE INCENTIVE SCHEME
Regulatory Filings Classification · 95% confidence The document is an announcement from Transcenta Holding Limited regarding the grant of award shares under its Share Incentive Scheme. It details the number of shares granted, the vesting period, performance targets, clawback mechanisms, and compliance with listing rules. There is no financial data, quarterly or annual results, or management discussion of financial performance. The document is a regulatory announcement about share awards to employees, not a financial report or earnings release. It fits the category of a Regulatory Filing (RNS) as it is a compliance announcement related to share incentive grants under listing rules.
2023-07-21 English
Next Day Disclosure Returns
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Transcenta Holding Limited. It details the issuance of new ordinary shares under a share award scheme, including the number of shares issued, dates, and prices. The document references compliance with listing rules of the Stock Exchange of Hong Kong and includes confirmations by the company's executive director. This type of document is a regulatory disclosure about share capital changes, specifically share issues, rather than a full financial report or earnings release. It fits the definition of a Share Issue/Capital Change announcement (SHA). The document length and content confirm it is not merely an announcement of a report but a substantive disclosure of capital changes.
2023-07-21 English
VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON APPROVALS FROM CHINA CDE AND SOUTH KOREA MFDS TO INITIATE TRANSTAR 301 GLOBAL PHASE III PIVOTAL TRIAL OF OSEMITAMAB (TST001)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Transcenta Holding Limited providing a business update on regulatory approvals to initiate a Phase III clinical trial for a drug candidate. It contains no financial statements, no detailed financial performance data, nor any regulatory filing forms or certifications. The content focuses on clinical trial progress and regulatory approvals, which is typical of a business update or operational announcement rather than a financial report or regulatory filing. The document is not an earnings release, annual report, or any form of financial report. It is also not a proxy, voting result, or management change announcement. Given the nature of the content and the absence of financial data, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2023-07-07 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.